www.klinickafarmakologie.cz / Klin Farmakol Farm. 2025;39(3):145-149 / KLINICKÁ FARMAKOLOGIE A FARMACIE 149 HLAVNÍ TÉMA Betablokátory v léčbě chronické ischemické choroby srdeční ženou EFLK, anginu pectoris nebo nedávno prodělali infarkt myokardu, u kterého je přínos léčby největší v prvním roce po události. U asymptomatických pacientů bez srdečního selhání lze léčbu BB zvážit, zejména při přítomnosti tachyarytmií nebo nekontrolované arteriální hypertenze. Ukončení terapie je vhodné při výskytu bradykardie, hypotenze či jiné intolerance. Vývoj reperfuzní katetrové léčby a moderní sekundární prevence změnil rizikový profil pacientů, což podtrhuje nutnost aktualizace doporučení kardiologických společností, zejména pokud jde o dlouhodobé užívání BB u stabilních pacientů s EFLK > 40 %. Léčba musí být vždy personalizována s ohledem na komorbidity a měla by zohledňovat farmakologické vlastnosti jednotlivých BB. LITERATURA 1. Widimský P, Rychlík I. Vnitřní lékařství: I. díl. Maxdorf; 2023. 2. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio- -Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3415-537. 3. Táborský M, Kautzner J, Linhart A, et al. Kardiologie: Svazek I-V. Grada Publishing a.s.; 2021. 4. Safi S, Sethi NJ, Nielsen EE, et al. Beta-blockers for suspected or diagnosed acute myocardial infarction. Cochrane Database Syst Rev. 2019;12(12):CD012484. 5. Vítovec J. Betablokátory v léčbě kardiovaskulárních onemocnění: Farmakoterapie pro klinickou praxi. Grada Publishing a.s.; 2023. 6. Khan O, Patel M, Tomdio AN, et al. Beta-Blockers in the Prevention and Treatment of Ischemic Heart Disease: Evidence and Clinical Practice. Heart Views. 2023;24(1):41-49. 7. Vítovec J, kolektiv. Léčba kardiovaskulárních onemocnění: 2., aktualizované a doplněné vydání. Grada Publishing a.s.; 2020. 8. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138(13):e272-391. 9. Ferrari R, Pavasini R, Camici PG, et al. Anti-anginal drugs- -beliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J. 2019;40(2):190-194. 10. Sorbets E, Steg PG, Young R, et al. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2019;40(18):1399-1407. 11. Dahl Aarvik M, Sandven I, Dondo TB, et al. Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2019;5(1):12-20. 12. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. The Lancet. 2001;357(9266):1385-1390. 13. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007. 14. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194-2199. 15. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13. 16. Rossello X, Raposeiras-Roubin S, Latini R, et al. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). Eur Heart J Cardiovasc Pharmacother. 2022;8(3):291-301. 17. Kim J, Kang D, Park H, et al. Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study. Eur Heart J. 2020;41(37):3521-3529. 18. Rossello X, Pocock SJ, Julian DG. Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care. J Am Coll Cardiol. 2015;66(11):1273-1285. 19. Cataldo MP, Gasevic D, Trin C, et al. Beta-Blocker Therapy After Myocardial Infarction. JACC: Advances. 2025;4(3):101582. 20. Watanabe H, Ozasa N, Morimoto T, et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLOS ONE. 2018;13(8):e0199347. 21. Yndigegn T, Lindahl B, Mars K, et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024;390(15):1372-1381. 22. Bangalore S, Bhatt DL, Steg PG, et al. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes. 2014;7(6):872-881. 23. Silvain J, Cayla G, Ferrari E, et al. Beta-Blocker Interruption or Continuation after Myocardial Infarction. New England Journal of Medicine. 2024;391(14):1277-1286. 24. Munkhaugen J, Ruddox V, Halvorsen S, et al. BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study. Am Heart J. 2019;208:37-46. 25. Kristensen AMD, Bovin A, Zwisler AD, et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. Trials. 2020;21(1):415. 26. Motivala AA, Parikh V, Roe M, et al. Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry. JACC: Cardiovascular Interventions. 2016;9(16):1639-1648. 27. Godoy LC, Farkouh ME, Austin PC, et al. Association of Beta-Blocker Therapy With Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease. JACC. 2023;81(24): 2299-2311. 28. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119-177. 29. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2021;42(14):1289-1367. 30. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2023;44(38):3720-3826. 31. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-119. 32. Vítovec J, Špinar J, Špinarová L. Betablokátory u kardiovaskulárních onemocnění – pro a proti. Kardiologická revue – Interní medicína. 2019(2):86-89. 33. Shu DF, Dong BR, Lin XF, et al. Long-term beta blockers for stable angina: systematic review and meta-analysis. Eur J Prev Cardiol. 2012;19(3):330-341.
RkJQdWJsaXNoZXIy NDA4Mjc=